TY - JOUR
T1 - A Hot Topic
T2 - Cancer Immunotherapy and Natural Killer Cells
AU - Michel, Tatiana
AU - Ollert, Markus
AU - Zimmer, Jacques
N1 - Funding Information:
Funding: This work was supported by grants from the Luxembourg National Research Fund (FNR) within the National Centre of Translational Cancer Research (NCTCR [FNR/I21/16632985/NCTCR]).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1/12
Y1 - 2022/1/12
N2 - Despite significant progress in recent years, the therapeutic approach of the multiple different forms of human cancer often remains a challenge. Besides the well-established cancer surgery, radiotherapy and chemotherapy, immunotherapeutic strategies gain more and more attention, and some of them have already been successfully introduced into the clinic. Among these, immunotherapy based on natural killer (NK) cells is considered as one of the most promising options. In the present review, we will expose the different possibilities NK cells offer in this context, compare data about the theoretical background and mechanism(s) of action, report some results of clinical trials and identify several very recent trends. The pharmaceutical industry is quite interested in NK cell immunotherapy, which will benefit the speed of progress in the field
AB - Despite significant progress in recent years, the therapeutic approach of the multiple different forms of human cancer often remains a challenge. Besides the well-established cancer surgery, radiotherapy and chemotherapy, immunotherapeutic strategies gain more and more attention, and some of them have already been successfully introduced into the clinic. Among these, immunotherapy based on natural killer (NK) cells is considered as one of the most promising options. In the present review, we will expose the different possibilities NK cells offer in this context, compare data about the theoretical background and mechanism(s) of action, report some results of clinical trials and identify several very recent trends. The pharmaceutical industry is quite interested in NK cell immunotherapy, which will benefit the speed of progress in the field
KW - Cancer
KW - Immunotherapy
KW - Natural killer cells
UR - http://www.scopus.com/inward/record.url?scp=85122495169&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/35054985
U2 - 10.3390/ijms23020797
DO - 10.3390/ijms23020797
M3 - Article
C2 - 35054985
SN - 1422-0067
VL - 23
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 2
M1 - 797
ER -